blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2970875

EP2970875 - CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  24.10.2025
Database last updated on 10.03.2026
FormerThe patent has been granted
Status updated on  13.03.2020
FormerGrant of patent is intended
Status updated on  21.10.2019
FormerExamination is in progress
Status updated on  05.10.2019
FormerGrant of patent is intended
Status updated on  27.05.2019
FormerExamination is in progress
Status updated on  13.12.2016
Most recent event   Tooltip24.10.2025Patent maintained (B2 publication)published on 26.11.2025  [2025/48]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2025/48]
Former [2020/16]For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Former [2016/03]For all designated states
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Inventor(s)01 / VIJAYASANKARAN, Natarajan
c/o Genentech Inc.
1 Dna Way
South San Francisco, CA 94080 / US
02 / MEIER, Steven, J.
c/o Genentech Inc.
1 Dna Way
South San Francisco, CA 94080 / US
03 / VARMA, Sharat
c/o Genentech Inc.
1 Dna Way
South San Francisco, CA 94080 / US
04 / YANG, Yi
c/o Genentech Inc.
1 Dna Way
South San Francisco, CA 94080 / US
 [2016/03]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2025/48]
Former [2016/03]Brodbeck, Michel, et al
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
Application number, filing date14721668.314.03.2014
[2016/03]
WO2014US29772
Priority number, dateUS201361799602P15.03.2013         Original published format: US 201361799602 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014145098
Date:18.09.2014
Language:EN
[2014/38]
Type: A1 Application with search report 
No.:EP2970875
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2970875
Date:15.04.2020
Language:EN
[2020/16]
Type: B2 New European patent specification 
No.:EP2970875
Date:26.11.2025
Language:EN
[2025/48]
Search report(s)International search report - published on:EP18.09.2014
ClassificationIPC:C07K16/00, C12N5/00
[2019/19]
CPC:
C12N5/0018 (EP,IL,KR,RU,US); C07K16/00 (IL,KR,RU,US); C07K2317/14 (IL,KR,US);
C12N2500/30 (EP,IL,KR,US); C12N2500/33 (EP,IL,KR,US); C12N2500/44 (IL,KR,US);
C12N2500/46 (IL,KR,US) (-)
Former IPC [2016/03]C12N5/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
TitleGerman:ZELLKULTURZUSAMMENSETZUNGEN MIT ANTIOXIDANZIEN UND VERFAHREN ZUR HERSTELLUNG VON POLYPEPTIDEN[2019/19]
English:CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION[2016/03]
French:COMPOSITIONS DE CULTURE DE CELLULES COMPRENANT DES ANTIOXYDANTS ET PROCÉDÉS DE PRODUCTION DE POLYPEPTIDES[2019/19]
Former [2016/03]ZELLKULTURZUSAMMENSETZUNGEN MIT ANTIOXIDANTIEN UND VERFAHREN ZUR POLYPEPTIDHERSTELLUNG
Former [2016/03]COMPOSITIONS DE CULTURE CELLULAIRE AYANT ANTI-OXYDANTS ET PROCÉDÉS POUR UNE PRODUCTION DE POLYPEPTIDE
Entry into regional phase15.10.2015National basic fee paid 
15.10.2015Designation fee(s) paid 
15.10.2015Examination fee paid 
Examination procedure15.10.2015Examination requested  [2016/03]
14.06.2016Amendment by applicant (claims and/or description)
09.08.2016Despatch of a communication from the examining division (Time limit: M06)
10.02.2017Reply to a communication from the examining division
18.10.2017Despatch of a communication from the examining division (Time limit: M06)
27.04.2018Reply to a communication from the examining division
14.05.2018Despatch of a communication from the examining division (Time limit: M06)
20.12.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
28.02.2019Reply to a communication from the examining division
28.05.2019Communication of intention to grant the patent
01.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.10.2019Communication of intention to grant the patent
04.03.2020Fee for grant paid
04.03.2020Fee for publishing/printing paid
04.03.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20168621.9  / EP3712252
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.08.2016
Opposition(s)Opponent(s)01  13.01.2021  15.01.2021  ADMISSIBLE
Hoffmann Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
Opponent's representative
Hoffmann Eitle, et al, et al
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 02  14.01.2021  18.01.2021  ADMISSIBLE
Maiwald GmbH
Elisenhof, Elisenstrasse 3
80335 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 [2025/15]
Former [2023/04]
Opponent(s)01  13.01.2021  15.01.2021  ADMISSIBLE
Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
 02  14.01.2021  18.01.2021  ADMISSIBLE
Maiwald GmbH
Elisenhof, Elisenstrasse 3
80335 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/16]
Opponent(s)01  13.01.2021  15.01.2021  ADMISSIBLE
Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
 02  14.01.2021  18.01.2021  ADMISSIBLE
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof, Elisenstrasse 3
80335 München / DE
Opponent's representative
Neuefeind, Regina
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/08]
Opponent(s)01  13.01.2021  15.01.2021  ADMISSIBLE
Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
 02  14.01.2021  18.01.2021  ADMISSIBLE
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Opponent's representative
Neuefeind, Regina
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
01.02.2021Invitation to proprietor to file observations on the notice of opposition
11.06.2021Reply of patent proprietor to notice(s) of opposition
12.10.2022Date of oral proceedings
11.11.2022Despatch of minutes of oral proceedings
11.03.2025Legal effect of interlocutory decision in opposition
05.08.2025Despatch of interlocutory decision in opposition
19.08.2025Despatch of communication that the patent will be maintained as amended
Appeal following opposition17.01.2023Appeal received No.  T0089/23
17.01.2023Payment of appeal fee
28.02.2023Statement of grounds filed
11.03.2025Result of appeal procedure: maintenance in amended form
05.08.2025Despatch of the decision of the Board of Appeal
11.03.2025Date of oral proceedings
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
28.02.2019Request for further processing filed
28.02.2019Full payment received (date of receipt of payment)
Request granted
13.03.2019Decision despatched
Fees paidRenewal fee
08.03.2016Renewal fee patent year 03
07.03.2017Renewal fee patent year 04
08.03.2018Renewal fee patent year 05
08.03.2019Renewal fee patent year 06
10.03.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2014
AL15.04.2020
CY15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
MK15.04.2020
MT15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
LU14.03.2021
[2024/41]
Former [2024/22]HU14.03.2014
AL15.04.2020
CY15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
MK15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
LU14.03.2021
Former [2023/30]HU14.03.2014
AL15.04.2020
CY15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
LU14.03.2021
Former [2023/27]HU14.03.2014
AL15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
LU14.03.2021
Former [2022/09]AL15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
LU14.03.2021
Former [2021/45]AL15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/11]AL15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/09]AL15.04.2020
CZ15.04.2020
DK15.04.2020
EE15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/08]AL15.04.2020
DK15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/04]AL15.04.2020
FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/01]FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
BG15.07.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/51]FI15.04.2020
LT15.04.2020
LV15.04.2020
RS15.04.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/48]FI15.04.2020
LT15.04.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/47]LT15.04.2020
NO15.07.2020
IS15.08.2020
Former [2020/46]IS15.08.2020
Cited inInternational search[XYI] WO9859035  (US HEALTH et al.)
 [XYI] WO2007050498  (WYETH CORP et al.)
 [X] WO2006116034  (GOLDSTEIN GLENN A et al.)
 [X] WO9209298  (PEPTIDE TECHNOLOGY LTD et al.)
 [X]   EREMEEVA ET AL: "Effects of the antioxidant alpha-lipoic acid on human umbilical vein endothelial cells infected with Rickettsia rickettsii.", INFECTION AND IMMUNITY, vol. 66, no. 5, 1 May 1998 (1998-05-01), pages 2290 - 2299, XP055128467, ISSN: 0019-9567
ExaminationEP0591605
   R.M. PETTERS ET AL: "Addition of taurine of hypotaurine to culture medium improves development of one- and two-cell pig embryos in vitro", THERIOGENOLOGY, vol. 35, no. 1, 1 January 1991 (1991-01-01), US, pages 253, XP055293337, ISSN: 0093-691X, DOI: 10.1016/0093-691X(91)90229-7

DOI:   http://dx.doi.org/10.1016/0093-691X(91)90229-7
by applicantUS4816567
 WO9824893
 WO9634096
 WO9633735
 WO9110741
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 US4767704
 US4657866
 US4927762
 US4560655
 WO9003430
 WO8700195
 USRE30985
 US5122469
 EP0307247
 US6180401
 US7189826
 US2006258841
 US2006183887
 US2006059575
 US2005287149
 US2005100546
 US2005026229
 US7078492
 US7153507
 WO9607754
 WO9209690
 WO9306213
 US5869046
 WO9316185
 US5571894
 US5587458
 US5641870
 WO9308829
 WO9404690
 WO9627011
 US4676980
 WO9100360
 WO9220373
 EP0003089
 US6248516
 WO9013646
 US4965199
 EP0073657
 US4419446
 US4601978
 WO9411026
 DD266710
 US5648237
 US5789199
 US5840523
 EP0402226
 EP0183070
 EP0244234
 US5959177
 US6040498
 US6420548
 US7125978
 US6417429
 US6267958
 US6171586
 WO2006044908
   LI ET AL., MABS, vol. 2, no. 5, 2010, pages 466 - 477
   "European Pharmacopoeia, 7th Ed.", 2008, pages: 22
   DAUGHERTY ET AL., ADV DRUG DELIVER REV, vol. 58, no. 5-6, 2006, pages 686 - 706
   KOHLER; MILSTEIN, NATURE, 1975, pages 495 - 97
   HONGO ET AL., HYBRIDOMA, vol. 14, no. 3, 1995, pages 253 - 260
   HARLOW ET AL.: "Antibodies: A Laboratory Manual, 2nd ed.", 1988, COLD SPRING HARBOR LABORATORY PRESS
   HAMMERLING ET AL.: "Monoclonal Antibodies and T-Cell Hybridomas", 1981, ELSEVIER, pages: 563 - 681
   CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597
   SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310
   LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093
   FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472
   LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132
   JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551
   JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
   BRUGGEMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33
   MARKS ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 779 - 783
   LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
   MORRISON, NATURE, vol. 368, 1994, pages 812 - 813
   FISHWILD ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 845 - 851
   NEUBERGER, NATURE BIOTECHNOL., vol. 14, 1996, pages 826
   LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
   A. GENNARO,: "Remington's Pharmaceutical Sciences (20th edition)", 2000, LIPPINCOTT, WILLIAMS & WILKINS
   "USP-24 Monograph 631 Color and Achromaticity", 2000, UNITED STATES PHARMACOPOEIA INC., pages: 1926 - 1927
   HAM; WALLACE, METH. ENZ., vol. 58, 1979, pages 44
   BARNES; SATO, ANAL. BIOCHEM., vol. 102, 1980, pages 255
   VIJAYASANKARAN ET AL., BIOMACROMOLECULES, vol. 6, 2005, pages 605 - 611
   PATKAR ET AL., J BIOTECHNOLOGY, vol. 93, 2002, pages 217 - 229
   SAMBROOK ET AL.,: "Molecular Cloning: A Laboratory Manual, 4th ed.,", 2012, COLD SPRING HARBOR LABORATORY PRESS
   F.M. AUSUBEL, ET AL.: "Current Protocols in Molecular Biology", 2003
   AUSUBEL ET AL.,: "Short Protocols in Molecular Biology", 2002, J. WILEY AND SONS
   HORSWILL ET AL., CURRENT PROTOCOLS IN PROTEIN SCIENCE, 2006
   HARLOW AND LANE: "Antibodies, A Laboratory Manual", 1988
   R.I. FRESHNEY,: "Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th ed.,", 2010, J. WILEY AND SONS
   KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
   NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268
   VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937
   VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91
   GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
   KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
   BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
   EVEN ET AL., TRENDS IN BIOTECHNOLOGY, vol. 24, no. 3, 2006, pages 105 - 108
   MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages 220
   HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37
   LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 93
   KABAT ET AL.: "Sequences of Proteins of Immunological Interest, Fifth Edition,", vol. 1-3, 1991, NIH PUBLICATION 91-3242
   WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455
   GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734
   WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388
   MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
   HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137
   ORLANDI ET AL., PROC. NATL. ACAD. SCI. (USA), vol. 86, 1989, pages 3833 - 3837
   WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
   JONES ET AL., BIOTECHNOL., vol. 9, 1991, pages 88 - 89
   SASTRY ET AL., PROC. NATL. ACAD. SCI. (USA), vol. 86, 1989, pages 5728 - 5732
   ORUM ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 4491 - 4498
   TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798
   MATSUDA ET AL., NATURE GENET., vol. 3, 1993, pages 88 - 94
   HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388
   BARBAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4457 - 4461
   WILLIAMS; WINTER, EUR. J. IMMUNOL., vol. 23, 1993, pages 1456 - 1461
   HOGREFE ET AL., GENE, vol. 128, 1993, pages 119 - 126
   WATERHOUSE ET AL., NUCL. ACIDS RES., vol. 21, 1993, pages 2265 - 2266
   BARBAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 7978 - 7982
   EMBLETON ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 3831 - 3837
   LEUNG ET AL., TECHNIQUE, vol. 1, 1989, pages 11 - 15
   HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
   GRAM ET AL., PROC. NATL. ACAD. SCI USA, vol. 89, 1992, pages 3576 - 3580
   MARKS ET AL., BIOTECHNOL., vol. 10, 1992, pages 779 - 783
   BARBAS ET AL., PROC. NATL. ACAD. SCI USA, vol. 88, 1991, pages 7978 - 7982
   BASS ET AL., PROTEINS, vol. 8, 1990, pages 309 - 314
   SKERRA ET AL., CURR. OPINION IN IMMUNOL., vol. 5, 1993, pages 256
   PLUCKTHUN, IMMUNOL. REVS, vol. 130, 1992, pages 151
   MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
   CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901
   CARTER ET AL., PROC. NATL. ACAD SCI. USA, vol. 89, 1992, pages 4285
   PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623
   BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86
   BRUGGERMANN ET AL., YEAR IN IMMUNO., vol. 7, 1993, pages 33
   DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
   HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
   MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
   BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
   CARTER ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 163 - 167
   MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
   TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
   SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210
   SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225
   KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
   HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
   GRUBER ET AL., J. IMMUNOL, vol. 152, 1994, pages 5368
   TUFT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
   STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39
   JONES, GENETICS, vol. 85, 1977, pages 12
   VAN DEN BERG, BIOLTECHNOLOGY, vol. 8, 1990, pages 135
   FLEER ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 968 - 975
   REYES ET AL., NATURE, vol. 297, 1982, pages 598 - 601
   YANIV, NATURE, vol. 297, 1982, pages 17 - 18
   CHARLTON: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254
   GERNGROSS, NAT. BIOTECH, vol. 22, 2004, pages 1409 - 1414
   LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215
   GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
   MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
   MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
   URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
   YAZAKI; WU: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRES, pages: 255 - 268
   LINDMARK ET AL., J. IMMUNOL., vol. 62, 1983, pages 1 - 13
   GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
   KELLEY, B., MABS., vol. 1, no. 5, 2009, pages 443 - 452
   "USP-24 Monograph 631 Color and Achromaticity", 2000, UNITED STATES PHARMACOPOEIA INC.,, pages: 1926 - 1927
   VIJAYASANKARAN ET AL., BIOTECHOL. PROG., vol. 29, 2013, pages 1270 - 1277
   BERNS ET AL.: "Billmeyer and Saltzman's Principles of Color Technology, 3rd Edition.", 2000, JOHN WILEY & SONS, INC.
   "Annual Book of ASTM Standards", vol. 06.01, 2011, article "Standard Practice for Calculation of Color Tolerances and Color Differences from Instrumentally Measured Color Coordinates"
   VIJAYASANKARAN ET AL., BIOTECHNOL PROG, vol. 27, 2013, pages 1270 - 1277
   EUROPEAN PHARMACOPOEIA, 2008, pages 22
   OSOL, A.: "Remington's Pharmaceutical Sciences 16th edition,", 1980
OppositionWO9859035
 WO2007050498
 EP0591605
 WO2009047007
 WO2011134919
 WO2013163294
 WO2006047380
 WO2006050050
 CN101418330
   PETTERS ET AL.: "Addition of taurine of hypotaurine to culture medium improves development of one- and two-cell pig embryos in vitro", THERIOGENOLOGY, vol. 35, no. 1, 1991, pages 253, XP055293337

DOI:   http://dx.doi.org/10.1016/0093-691X(91)90229-7
   VIJAYASANKARAN ET AL.: "Effect of Cell Culture Medium Components on Color of Formulated Monoclonal Antibody Drug Substance", BIOTECHNOL PROG, vol. 29, no. 5, 2013, pages 1270 - 7, XP055780336
   SEN ET AL.: "Development of optimal medium for production of commercially important monoclonal antibody 520C9 by hybridoma cell", CYTOTECHNOLOGY, vol. 65, no. 2, 19 July 2012 (2012-07-19), pages 233 - 252, XP055780338
   HECKLAU ET AL.: "S-Sulfocysteine simplifies fed-batch processes and increases the CHO specific productivity via anti-oxidant activity", J BIOTECHNOL, vol. 218, 2016, pages 53 - 63, XP029379422

DOI:   http://dx.doi.org/10.1016/j.jbiotec.2015.11.022
   STIPANUK ET AL.: "Mammalian Cysteine Metabolism: New Insights into Regulation of Cysteine Metabolism", J NUTR., vol. 136, no. 6 Suppl, 2006, pages 1652S - 1659S, XP002626793
   LIU ET AL.: "Recovery and purification process development for monoclonal antibody production", MABS, vol. 2, no. 5, 2010, pages 480 - 99, XP002691388

DOI:   http://dx.doi.org/10.4161/mabs.2.5.12645
   MCKENNA: "Oxidative stress on mammalian cell cultures during recombinant protein expression", LINKPING STUDIES IN SCIENCE AND TECHNOLOGY LICENTIATE THESIS, 2009, XP055780346
   ARUOMA ET AL.: "The antioxidant action of taurine, hypotaurine and their metabolic precursors", BIOCHEM J., vol. 256, no. 1, 1988, pages 251 - 255, XP055780350
   GUERIN ET AL.: "Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and itssurroundings", HUM REPROD UPDATE, vol. 7, no. 2, 2001, pages 175 - 89, XP055780358
   OKEZIE I. ARUOMA, ,* BARRY HALLIWELL,*+ BRIGID M. HOEYT AND JOHN BUTLER: "The antioxidant action of taurine, hypotaurine and their metabolic precursors", BIOCHEM J., vol. 256, 1 January 1988 (1988-01-01), pages 251 - 255, XP055780350
   VIJAYASANKARAN NATARAJAN, VARMA SHARAT, YANG YI, MEIER STEVEN, KISS ROBERT: "Effect of cell culture medium additives on color and acidic charge variants of a monoclonal antibody", BIOTECHNOLOGY PROGRESS, AMERICAN CHEMICAL SOCIETY, vol. 34, no. 5, 9 August 2018 (2018-08-09), pages 1298 - 1307, XP055875309, ISSN: 8756-7938, DOI: 10.1002/btpr.2668

DOI:   http://dx.doi.org/10.1002/btpr.2668
   QI ET AL.: "Characterization of the Photodegradation of a Human IgG1 Monoclonal Antibody Formulated as a High- Concentration Liquid Dosage Form", J. PHARM. SCI., vol. 98, no. 9, 2009, pages 3117 - 3130, XP002592759, DOI: 10.1002/JPS.21617

DOI:   http://dx.doi.org/10.1002/JPS.21617
   NADINE KOCHANOWSKI;GAETAN SIRIEZ;SARAH ROOSENS;LAETITIA MALPHETTES: "Medium and feed optimization for fed-batch production of a monoclonal antibody in CHO cells", BMC PROCEEDINGS, BIOMED CENTRAL LTD, LONDON UK, vol. 5, no. Suppl 8, 22 November 2011 (2011-11-22), London UK , pages P75, XP021114454, ISSN: 1753-6561, DOI: 10.1186/1753-6561-5-S8-P75

DOI:   http://dx.doi.org/10.1186/1753-6561-5-S8-P75
   MOSSER MATHILDE, ET AL: "Combination of yeast hydrolysates to improve CHO cell growth and IgG production", CYTOTECHNOLOGY, SPRINGER NETHERLANDS, DORDRECHT, vol. 65, no. 4, 1 August 2013 (2013-08-01), Dordrecht, pages 629 - 641, XP055960499, ISSN: 0920-9069, DOI: 10.1007/s10616-012-9519-1

DOI:   http://dx.doi.org/10.1007/s10616-012-9519-1
   LI ET AL.: "Cell culture processes for monoclonal antibody production", MABS, vol. 2, no. 5, 2010, pages 466 - 477, XP055166177, DOI: 10.4161/mabs.2.5.12720

DOI:   http://dx.doi.org/10.4161/mabs.2.5.12720
   ZHANG ET AL.: "Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody", CYTOTECHNOL, vol. 65, August 2012 (2012-08-01), pages 363 - 378, XP055615804, DOI: 10.1007/s10616-012-9488-4

DOI:   http://dx.doi.org/10.1007/s10616-012-9488-4
   NATARAJAN VIJAYASANKARAN ET AL: "Effect of Cell Culture Medium Components on Color of Formulated Monoclonal Antibody Drug Substance", BIOTECHNOL PROG, vol. 29, no. 5, pages 1270 - 1277, XP055780336
   QI ET AL.: "Characterization of the Photodegradation of a Human IgG1 Monoclonal Antibody Formulated as a High- Concentration Liquid Dosage Form", J. PHARM. SCI., vol. 98, no. 9, 2009, pages 3117 - 3130, XP002592759, DOI: 10.1002/JPS.21617

DOI:   http://dx.doi.org/10.1002/JPS.21617
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.